Scan Results
Daily timeframeMaze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. At a $1.32B market cap, Maze Therapeutics, Inc. ranks as a small-cap company within healthcare. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease.
Market Cap
$1.32B
Beta
—
P/E (TTM)
—
P/E (Fwd)
-7.24
EPS (TTM)
$-2.35
EPS (Fwd)
$-3.31
ROE
-38.7%
ROA
-22.3%
Cash
$352.4M
Total Debt
$61.2M
Free CF
-$81.7M
52W Change
84.5%
Annual Financials
Cash vs Debt
With $352.4M in cash and $61.2M in debt, MAZE maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$81.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -38.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, MAZE has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Maze Therapeutics, Inc.'s trajectory.